PEAK6 Group’s AstraZeneca AZN Stock Holding History

PEAK6 Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-24,574	Closed	-$1.77M	–	4300
2018 Q1	$1.72M	Buy	+24,574	New	+$1.7M	0.01%	1503
2017 Q3	–	Sell	-128,924	Closed	-$8.14M	–	4375
2017 Q2	$8.79M	Buy	128,924 +109,602	+567%	+$7.16M	0.05%	436
2017 Q1	$1.2M	Buy	19,322 +8,929	+86%	+$520K	0.01%	1531
2016 Q4	$568K	Sell	10,393 -34,169	-77%	-$1.94M	﹤0.01%	2391
2016 Q3	$2.93M	Buy	44,562 +43,568	+4,383%	+$2.85M	0.02%	1024
2016 Q2	$60K	Sell	994 -16,364	-94%	-$950K	﹤0.01%	3795
2016 Q1	$978K	Buy	+17,358	New	+$1.04M	0.01%	1681
2015 Q4	–	Sell	-166,379	Closed	-$10.9M	–	4724
2015 Q3	$10.6M	Buy	166,379 +85,850	+107%	+$5.65M	0.06%	443
2015 Q2	$5.13M	Buy	+80,529	New	+$5.51M	0.03%	823
2015 Q1	–	Sell	-47,022	Closed	-$3.27M	–	4732
2014 Q4	$3.31M	Sell	47,022 -2,820	-6%	-$202K	0.03%	918
2014 Q3	$3.56M	Sell	49,842 -87,300	-64%	-$6.39M	0.03%	843
2014 Q2	$10.2M	Buy	137,142 +125,987	+1,129%	+$9.11M	0.1%	238
2014 Q1	$724K	Buy	+11,155	New	+$720K	0.01%	2168

Other funds holding AZN

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

EIP

Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return

PEAK6 Group's AZN Position: Q2 2018 in Review

PEAK6 Group sold out of AstraZeneca (AZN) in Q2 2018, closing a stake of 24,574 shares — an estimated $1.77M sold.

PEAK6 Group first reported a position in AZN in Q1 2014 and held it in 13 quarters. The position peaked at $10.6M in Q3 2015. 530 funds tracked by Wall St. Rank hold AZN as of Q2 2018.

PEAK6 Group reported no remaining AstraZeneca position as of Q2 2018 after selling out during the quarter.
PEAK6 Group sold 24,574 AstraZeneca shares in Q2 2018, an estimated $1.77M.
PEAK6 Group first reported a position in AstraZeneca in Q1 2014 and held it in 13 quarters.
PEAK6 Group's AstraZeneca position peaked at $10.6M in Q3 2015.
530 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2018.

Based on PEAK6 Group's 13F filing for Q2 2018, filed 15 Aug 2018.